CClinicalTrials.gg
RecruitingNCT07063173Tart CherryUpdated Dec 29, 2025

Bioavailability of Ration Items Containing Tart Cherry Extract

An interventional study of Fruit Bar and Powdered Drink in Bioavailability, sponsored by United States Army Research Institute of Environmental Medicine. Recruiting at 1 site in United States. Open to participants aged 17 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by United States Army Research Institute of Environmental Medicine · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
17 Years to 39 Years
Sex
All
01

Study summary

To determine how consuming food items containing shelf-stored tart cherry impacts your body's ability to absorb and use the compounds within tart cherry.

Read the detailed description

Consumption of tart cherry (TC) products may have beneficial effects on military performance. For example, in-vitro and in-vivo evidence indicates the benefits of TC products on muscle. This includes reduced muscle damage, muscle soreness and strength decrements after resistance exercise; and increased antioxidant capacity, reduced inflammation and reduced lipid peroxidation following endurance exercise. Prior to assessing potential performance benefits, DEVCOM-Soldier Center's Combat Feeding Division (CFD) is seeking to determine the effect of shelf-stable tart cherry powder (TCP)-containing food items on the bioavailability and absorption of polyphenols in humans.

The primary objective of his study is to evaluate the postprandial concentrations of anthocyanins, anthocyanidins, flavonols, phenolic acids, and their degradation products in response to a TCP-containing, shelf-stable bar and shelf-stable powdered drink, compared to a non-TCP containing control item and a TC-containing commercial item. Secondary objectives are to determine postprandial polyphenol absorption via urine concentrations of anthocyanins, anthocyanidins, flavonols, phenolic acids and their degradation products; and circulating antioxidant capacity. Active-duty military personnel and civilians will be invited to participate in the study if they are between the ages of 18 (or 17 for military personnel) and 39, are willing to participate in all study procedures and comply with all study instruction and pass a general medical clearance.

In this randomized, crossover study, participants will consume three different food products containing TC component and a control (food item without TC) over four different sessions. Each session will be followed by a five-day washout period. On the day of each experimental session, and after verification of compliance with study procedures (e.g., overnight fast and low polyphenol diet day prior…), an IV catheter will be inserted, and an initial blood sample will be collected. Immediately following, volunteers will consume either: 1) commercially available TC juice ("gold standard"), 2) CFD-formulated snack bar containing TCP, 3) CFD-formulated powdered drink containing TCP, or 4) CFD-formulated beverage containing no polyphenols (Figure 1). TC containing treatments will be matched by total anthocyanin content (\~120 mg total). Blood samples will be collected on the day of each session and the day after for measurement of circulating phenolic compounds (by CFD using LC-MS). Biomarkers of oxidation and anti-oxidation will also be measured, along with associations between study outcomes and gut microbiome composition. Complete data will be collected for up to 15 participants.

02

Conditions studied

  • Bioavailability

Keywords

  • military
  • tart cherry
  • muscle recovery
  • polyphenols
03

Who can participate

Ages eligible
17 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Active duty military personnel and civilians will be invited to participate in the study if they:

    • Are between the ages of 18 (or 17 for military personnel) and 39.
    • Are willing to participate in all study procedures and comply with all study instruction.
    • In good health as determined by OMSO (Office of Medical Support and Oversight).
    • Supervisor approval for federal civilian employees and non-HRV active-duty military personnel stationed at NSSC

Exclusion criteria

Exclusion Criteria:

    • Unable to understand verbal or written instructions or testing materials in English.

      • Have a bleeding disorder (e.g., von Willebrand Disease, hemophilia) or are being treated with medication that will impair blood clotting (for example, coumadin)
      • Have a history of GI-related conditions that may impact macronutrient absorption (e.g., Crohn's disease, ulcerative colitis, Celiac's disease or gluten sensitivity, bariatric surgery or gastroparesis, short bowel, inflammatory bowel disease, etc…);
      • Any use of antibiotics or antifungal, except topical antibiotics/antifungals within 3 months of study participation.
      • Colonoscopy within 3 months of study participation.
      • Regular (i.e., weekly or more frequent) use of over-the-counter medications (including antacids, laxatives, stool softeners, and antidiarrheals) unless approved by OMSO and study PI.
      • Are habitually taking nonsteroidal anti-inflammatory drugs (e.g., Advil, aspirin), corticosteroids (e.g., prednisone) or immunosuppressants (e.g. Humira);
      • Have an allergy or aversion (extreme dislike) to any of the test foods(e.g., cherry flavored beverages or bar). Allergy symptoms may include anaphylaxis, hives or eczema, tingling/itching in the mouth, dizziness or fainting, diarrhea, nausea or vomiting, swelling of the lips, face, tongue and throat).
      • Have donated blood within the past 8 weeks of the first test session or plan to donate blood during the study.
      • Are not willing to abstain from tobacco products and vigorous exercise for at least 24 hours" before each trial and consume a low-polyphenol diet two days prior to each test session and on the day of the test session.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Active comparator
    Tart Cherry Juice

    The commercially available tart cherry (TC) drink contains 100% concentrated Montmorency cherry juice (CherryActive, Sunbury, UK) as a "gold standard". Participants will consume 60 mL of the concentrate diluted with 500 mL of water, which delivers \~120 mg of anthocyanins.

    Dietary Supplement: Fruit Bar · Dietary Supplement: Powdered Drink · Dietary Supplement: Placebo beverage

  • Active comparator
    Fruit Bar

    The fruit powder is incorporated into a snack bar, which delivers \~120 mg of anthocyanins.

    Dietary Supplement: Powdered Drink · Dietary Supplement: Commercially available 100% tart cherry juice · Dietary Supplement: Placebo beverage

  • Active comparator
    Powdered Drink

    The fruit powder is incorporated into a powdered drink, which delivers \~120 mg of anthocyanins..

    Dietary Supplement: Fruit Bar · Dietary Supplement: Commercially available 100% tart cherry juice · Dietary Supplement: Placebo beverage

  • Placebo comparator
    Control Beverage

    A control powdered drink will be formulated with similar organoleptic qualities to the TCP-containing powdered drink without containing any polyphenol-rich ingredients.

    Dietary Supplement: Fruit Bar · Dietary Supplement: Powdered Drink · Dietary Supplement: Commercially available 100% tart cherry juice

Interventions

  • Dietary supplementFruit Bar

    Tart Cherry N185

    Also known as: Tart Cherry N185

  • Dietary supplementPowdered Drink

    Vita Cherry Sport N1244 (FutureCeuticals, Momence, IL)

    Also known as: Vita Cherry Sport N1244

  • Dietary supplementCommercially available 100% tart cherry juice

    100% concentrated Montmorency cherry juice (CherryActive, Sunbury, UK)

    Also known as: "gold standard" beverage

  • Dietary supplementPlacebo beverage

    Placebo beverage

05

What researchers measure

Primary outcomes

  1. Postprandial concentrations of polyphenols in plasma

    The primary objective of this study is to evaluate the postprandial concentrations of: * nmol/L for anthocyanins \& anthocyanidins (cyanidin-3-glucosylrutinoside, cyanidin-3-rutinoside,cyanidin-3-sophoroside, cyanidin-3-glucoside, cyanidin, peonidin-3-glucoside and pelargonidin); * µmol/L for flavonols (Isorhamnetin-3-rutinoside, kaemperol, and que after consuming a TCP-containing, shelf-stable bar and shelf-stable powdered drink (compared to a non-TCP containing control and a TC-containing commercial item).

    Time frame: Baseline and postprandially @ 30-minutes, 60-minutes, 120-minutes, 240-minutes, 360-mins, 24 hours

Secondary outcomes

  1. Postprandial concentrations of polyphenols in urine

    Secondary objectives are to determine postprandial polyphenol absorption via urine concentrations of anthocyanins, anthocyanidins, flavonols, phenolic acids and their degradation products as well as circulating antioxidant capacity; and to determine associations between these outcomes and gut microbiome composition

    Time frame: Baseline and postprandially @ Baseline and postprandially @ 30-minutes, 60-minutes, 120-minutes, 240-minutes, 360-mins, 24 hours

06

Study locations

1 of 1 sites recruiting
07

References and documents

Study documents

  • Informed consent form · Mar 20, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — The principal investigator, with the assistance of associate investigators and project coordinator, will continuously evaluate recruitment, the informed consent process, adverse events, and protocol adherence and deviations in order to identify unanticipated problems or risks to the participants associated with the research. The principal investigator will ensure that the number of participants recruited for this study complies with the protocol. The principal investigator will be responsible for continually monitoring that data for each participant is collected and analyzed as specified in this protocol, and for ensuring that study files and IRB documentation are appropriate and up to date. The principal investigator and OMSO staff will discuss "discontinuation criteria" for individual participants as the study progresses, based on their observations of the participant during testing or non-testing periods.

08

Registry details

Key details

Study ID
NCT07063173
Lead sponsor
United States Army Research Institute of Environmental Medicine
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Jun 14, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Dec 29, 2025

Study contacts

Tracey J Smith, PhD
Contact
tracey.smith10.civ@health.mil
5082062390 ext. 2390
Robert Roussel, PhD
Contact
robert.r.roussel.civ@health.mil
Tracey Smith, PhD
principal investigator · United States Army Research Institute of Environmental Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion